Literature DB >> 3337615

Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects.

D S Charney1, W K Goodman, L H Price, S W Woods, S A Rasmussen, G R Heninger.   

Abstract

To evaluate the role of serotonin (5-HT) function in obsessive-compulsive disorder (OCD), behavioral and biochemical responses to the 5-HT receptor agonist m-chlorophenylpiperazine (MCPP) and the 5-HT precursor tryptophan were examined in healthy subjects and patients with OCD. Baseline prolactin levels and the prolactin rise following MCPP were significantly reduced in female patients compared with female healthy subjects. In contrast, the increase in prolactin level following tryptophan administration was not significantly different between male or female patients with OCD and the respective sex-matched healthy subjects. The prolactin responses to MCPP and tryptophan were both significantly higher in female patients and healthy subjects than in their male counterparts. The cortisol and growth hormone responses to MCPP and tryptophan were similar in the patients and healthy subjects and were not related to gender. The behavioral responses to MCPP or tryptophan were not consistently different between patients and healthy subjects, and neither MCPP nor tryptophan had effects on obsessive or compulsive symptoms. These results lend only partial support to the hypothesis that 5-HT dysfunction may be linked to the pathophysiology of OCD and point to the need for the evaluation of other neurotransmitter systems in future investigations of OCD.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3337615     DOI: 10.1001/archpsyc.1988.01800260095012

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  23 in total

1.  Separate mechanisms for development and performance of compulsive checking in the quinpirole sensitization rat model of obsessive-compulsive disorder (OCD).

Authors:  Mark C Tucci; Anna Dvorkin-Gheva; Renee Sharma; Leena Taji; Paul Cheon; John Peel; Ashley Kirk; Henry Szechtman
Journal:  Psychopharmacology (Berl)       Date:  2014-02-28       Impact factor: 4.530

Review 2.  Second generation antipsychotic-induced obsessive-compulsive symptoms in schizophrenia: a review of the experimental literature.

Authors:  Trehani M Fonseka; Margaret A Richter; Daniel J Müller
Journal:  Curr Psychiatry Rep       Date:  2014-11       Impact factor: 5.285

3.  Pentagastrin has panic-inducing properties in obsessive compulsive disorder.

Authors:  A S de Leeuw; J A Den Boer; B R Slaap; H G Westenberg
Journal:  Psychopharmacology (Berl)       Date:  1996-08       Impact factor: 4.530

4.  Obsessive compulsive neurosis : clomipramine, prolactin and therapeutic response.

Authors:  J Ananth; A Kaur; R Poland; M Wohl
Journal:  Indian J Psychiatry       Date:  1997-04       Impact factor: 1.759

5.  Sleep EEG of patients with obsessive-compulsive disorder.

Authors:  F Hohagen; S Lis; S Krieger; G Winkelmann; D Riemann; R Fritsch-Montero; E Rey; J Aldenhoff; M Berger
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

6.  Experimental studies on 3,4-methylenedioxymethamphetamine (MDA, "ecstasy") and its potential to damage brain serotonin neurons.

Authors:  G A Ricaurte; U D McCann
Journal:  Neurotox Res       Date:  2001-01       Impact factor: 3.911

7.  Dopaminergic and serotonergic modulation of persistent behaviour in the reinforced spatial alternation model of obsessive-compulsive disorder.

Authors:  Dimitris Kontis; Vasileios Boulougouris; Vasiliki Maria Papakosta; Stamatina Kalogerakou; Socrates Papadopoulos; Cornelia Poulopoulou; George N Papadimitriou; Eleftheria Tsaltas
Journal:  Psychopharmacology (Berl)       Date:  2008-07-14       Impact factor: 4.530

8.  Effects of the serotonergic agonist mCPP on male rats in the quinpirole sensitization model of obsessive-compulsive disorder (OCD).

Authors:  Mark C Tucci; Anna Dvorkin-Gheva; Dawn Graham; Sean Amodeo; Paul Cheon; Ashley Kirk; John Peel; Leena Taji; Henry Szechtman
Journal:  Psychopharmacology (Berl)       Date:  2013-01-25       Impact factor: 4.530

9.  A dose-response study of intravenous m-chlorophenylpiperazine in normal subjects.

Authors:  O Kalus; S Wetzler; R S Kahn; G M Asnis; H M van Praag
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 10.  Eating disorder and obsessive-compulsive disorder: neurochemical and phenomenological commonalities.

Authors:  J L Jarry; F J Vaccarino
Journal:  J Psychiatry Neurosci       Date:  1996-01       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.